Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes

Autores da FMUP
Participantes de fora da FMUP
- Sharma, A
- Angelico Goncalves, A
- Leite, AR
- Packer, M
- Zannad, F
- Leite Moreira, A.
Unidades de investigação
Abstract
Aim Glucagon-like peptide-1 receptor agonists (GLP1-RA) improve cardiovascular outcomes in patients with type 2 diabetes (T2D). However, some studies suggest that their effects in patients with heart failure (HF) may be attenuated. We aimed to explore the effects of the GLP1-RA albiglutide on HF outcomes in patients with and without HF history enrolled in the Harmony Outcomes trial. Methods and results Harmony Outcomes enrolled patients with T2D and cardiovascular disease randomized to either albiglutide or placebo over a median follow-up of 1.6 years. A total of 9462 patients were included, of whom 1922 (20%) had HF history. Patients with HF had more cardiovascular comorbidities, poorer renal function, and had a three to four-fold higher risk of HF events compared to patients without HF. Compared to placebo, the effect of albiglutide on the composite of cardiovascular death or HF hospitalization was more pronounced among patients without HF (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56-0.95) than in patients with HF (HR 1.06, 95% CI 0.79-1.43) (interaction p = 0.062). A similar pattern was observed for HF hospitalizations (interaction p = 0.025). The effect of albiglutide on cardiovascular death, sudden death or 'pump failure' death, and all-cause mortality was also attenuated among patients with HF history, but without significant interaction (p > 0.1). The benefit of albiglutide to reduce atherosclerotic events was consistent regardless of HF history. Conclusions In patients with T2D and cardiovascular disease, albiglutide appeared to have no effect in reducing HF-related events among patients with HF history. These findings, placed in the context of other trials, suggest that GLP1-RA may not improve HF outcomes in patients with HF.
© 2022 European Society of Cardiology.
Dados da publicação
- ISSN/ISSNe:
- 1388-9842, 1879-0844
- Tipo:
- Article
- Páginas:
- 1792-1801
- DOI:
- 10.1002/ejhf.2660
- Link para outro recurso:
- www.scopus.com
European Journal of Heart Failure Wiley-Blackwell
Citações Recebidas na Web of Science: 13
Citações Recebidas na Scopus: 18
Documentos
- Não há documentos
Filiações
Keywords
- Albiglutide; Glucagon-like peptide-1 receptor agonists; Type 2 diabetes; Heart failure
Campos de estudo
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Comparação de escala de qualidade de vida na insuficiência cardíaca com fração de ejeção reduzida quando realizada no domicílio ou na consulta hospitalar.
Investigador Principal: Francisco Aguiar Vasques Novoa Faria
Estudo Observacional Académico (QualidadeIC) . 2021
Evaluation of thyroid function in patients hospitalized for acute heart failure
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico (Heart failure) . 2021
Predictors Of The Effectiveness Of Insulin Pumps In Patiens With Type 1 Diabetes Mellitus
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico . 2021
Impacto da pandemia COVID-19 no controlo metabólico de doentes com Diabetes Mellitus Tipo 1
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico . 2022
Influence of Diabetes on Response to Ultrasound Guided Hydrodistension Treatment of Adhesive Capsulitis: a Retrospective Study
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico (Hydrodistension ) . 2022
Influence of Cystic Fibrosis-Related Diabetes on the Severity of Cystic Fibrosis Phenotype
Investigador Principal: João Sérgio de Lima Soares Neves
Estudo Clínico Académico . 2022
Acromegalia: Metabolismo da Glicose Como Possível Preditor de Tumores Mais Agressivos
Investigador Principal: Davide Maurício Costa Carvalho
Estudo Clínico Académico . 2022
Diabetic Neuropathy, Central Nervous System Plasticity and Metabolic Disfunction
Investigador Principal: Davide Maurício Costa Carvalho
Estudo Clínico Académico . 2020
Citar a publicação
Ferreira J,Sharma A,Vasques F,Angelico A,Leite AR,Borges M,Carvalho D,Packer M,Zannad F,Leite A,Neves J. Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes. Eur. J. Heart Fail. 2022. 24. (10):p. 1792-1801. IF:18,200. (1).